These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 32870522

  • 1. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin.
    Hassan R, Alewine C, Mian I, Spreafico A, Siu LL, Gomez-Roca C, Delord JP, Italiano A, Lassen U, Soria JC, Bahleda R, Thomas A, Steinberg SM, Peer CJ, Figg WD, Niederfellner G, Méresse Naegelen V, Pastan I.
    Cancer; 2020 Nov 15; 126(22):4936-4947. PubMed ID: 32870522
    [Abstract] [Full Text] [Related]

  • 2. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
    Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, Kreitman RJ, Steinberg SM, Hollevoet K, Pastan I.
    Cancer; 2014 Nov 01; 120(21):3311-9. PubMed ID: 24989332
    [Abstract] [Full Text] [Related]

  • 3. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.
    Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I.
    Clin Cancer Res; 2007 Sep 01; 13(17):5144-9. PubMed ID: 17785569
    [Abstract] [Full Text] [Related]

  • 4. Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models.
    Jiang Q, Ghafoor A, Mian I, Rathkey D, Thomas A, Alewine C, Sengupta M, Ahlman MA, Zhang J, Morrow B, Steinberg SM, Pastan I, Hassan R.
    Sci Transl Med; 2020 Jul 01; 12(550):. PubMed ID: 32611684
    [Abstract] [Full Text] [Related]

  • 5. Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors.
    Hagerty BL, Pegna GJ, Xu J, Tai CH, Alewine C.
    Biomolecules; 2020 Jun 28; 10(7):. PubMed ID: 32605175
    [Abstract] [Full Text] [Related]

  • 6. Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors.
    Mazor R, Zhang J, Xiang L, Addissie S, Awuah P, Beers R, Hassan R, Pastan I.
    Mol Cancer Ther; 2015 Dec 28; 14(12):2789-96. PubMed ID: 26443804
    [Abstract] [Full Text] [Related]

  • 7. An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models.
    Scales SJ, Gupta N, Pacheco G, Firestein R, French DM, Koeppen H, Rangell L, Barry-Hamilton V, Luis E, Chuh J, Zhang Y, Ingle GS, Fourie-O'Donohue A, Kozak KR, Ross S, Dennis MS, Spencer SD.
    Mol Cancer Ther; 2014 Nov 28; 13(11):2630-40. PubMed ID: 25249555
    [Abstract] [Full Text] [Related]

  • 8. Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma.
    Alewine C, Ahmad M, Peer CJ, Hu ZI, Lee MJ, Yuno A, Kindrick JD, Thomas A, Steinberg SM, Trepel JB, Figg WD, Hassan R, Pastan I.
    Clin Cancer Res; 2020 Feb 15; 26(4):828-836. PubMed ID: 31792036
    [Abstract] [Full Text] [Related]

  • 9. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.
    Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I.
    Clin Cancer Res; 2009 Aug 15; 15(16):5274-9. PubMed ID: 19671873
    [Abstract] [Full Text] [Related]

  • 10. Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures.
    Liu W, Tai CH, Liu X, Pastan I.
    Proc Natl Acad Sci U S A; 2022 Nov 29; 119(48):e2214928119. PubMed ID: 36409889
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxin.
    Liu XF, FitzGerald DJ, Pastan I.
    Cancer Res; 2013 Apr 01; 73(7):2281-8. PubMed ID: 23348423
    [Abstract] [Full Text] [Related]

  • 13. Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
    Hassan R, Thomas A, Alewine C, Le DT, Jaffee EM, Pastan I.
    J Clin Oncol; 2016 Dec 01; 34(34):4171-4179. PubMed ID: 27863199
    [Abstract] [Full Text] [Related]

  • 14. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.
    Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, Waldmann TA, Pastan I.
    J Clin Oncol; 2000 Apr 01; 18(8):1622-36. PubMed ID: 10764422
    [Abstract] [Full Text] [Related]

  • 15. Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1.
    Ali-Rahmani F, FitzGerald DJ, Martin S, Patel P, Prunotto M, Ormanoglu P, Thomas C, Pastan I.
    Cancer Res; 2016 Mar 15; 76(6):1560-8. PubMed ID: 26719540
    [Abstract] [Full Text] [Related]

  • 16. New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma.
    Zhang YF, Phung Y, Gao W, Kawa S, Hassan R, Pastan I, Ho M.
    Sci Rep; 2015 May 21; 5():9928. PubMed ID: 25996440
    [Abstract] [Full Text] [Related]

  • 17. Mesothelin-targeted agents in clinical trials and in preclinical development.
    Kelly RJ, Sharon E, Pastan I, Hassan R.
    Mol Cancer Ther; 2012 Mar 21; 11(3):517-25. PubMed ID: 22351743
    [Abstract] [Full Text] [Related]

  • 18. Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.
    Awuah P, Bera TK, Folivi M, Chertov O, Pastan I.
    Mol Cancer Ther; 2016 Jul 21; 15(7):1648-55. PubMed ID: 27196771
    [Abstract] [Full Text] [Related]

  • 19. Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors.
    El-Behaedi S, Landsman R, Rudloff M, Kolyvas E, Albalawy R, Zhang X, Bera T, Collins K, Kozlov S, Alewine C.
    Toxins (Basel); 2018 Oct 31; 10(11):. PubMed ID: 30384408
    [Abstract] [Full Text] [Related]

  • 20. Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer.
    Bera TK, Williams-Gould J, Beers R, Chowdhury P, Pastan I.
    Mol Cancer Ther; 2001 Dec 31; 1(2):79-84. PubMed ID: 12467225
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.